Comparative Pharmacology
Head-to-head clinical analysis: E E S 200 versus ERYGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 200 versus ERYGEL.
E.E.S. 200 vs ERYGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also inhibit ribosomal assembly.
Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking the translocation of peptidyl-tRNA.
400 mg orally every 6 hours as the ethylsuccinate salt. Maximum daily dose 4 g.
Apply a thin layer to affected areas twice daily. Topical use only.
None Documented
None Documented
Approximately 1.5-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in severe renal impairment.
Terminal elimination half-life is approximately 1.6 hours (range 1.0–2.5 hours) after topical application, too short to accumulate with daily use.
Primarily hepatic metabolism and biliary excretion; approximately 5-15% of active drug excreted renally, with fecal elimination accounting for the majority of the remaining dose.
Primarily hepatic metabolism; less than 10% excreted renally as unchanged drug. Biliary excretion is minimal.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic